Among 19 receptor kinase families identified in the human genome (Robinson et al., 2000), ALK, EGFR, MET, and RET tyrosine kinases have become targets for the treatment of NSCLC (Broekman et al., 2011). The gene discussed is RET; the disease is non-small cell lung carcinoma.